What the scan actually measures
Calcium is not the plaque itself. It is what the artery wall deposits as older plaque stabilises and hardens — a fingerprint of atherosclerosis that has been there long enough to mineralise. The CT counts those deposits and weights them by density; the total is the Agatston score. No contrast dye, no IV, no treadmill, no fasting. You lie still, hold your breath a few times, and leave.
That distinction matters more than it sounds. Risk calculators estimate what should be happening in someone with your numbers. A calcium score reports what is happening in you. Two women with identical cholesterol, blood pressure and family history can have scores of 0 and 340. That gap is the whole argument for the test.
Who is the test genuinely for?
The American Heart Association frames the best candidate plainly: someone who is unsure about starting a statin, or considering restarting one after stopping because of side effects, and who wants more clarity on their risk. The 2018 ACC/AHA/multisociety cholesterol guideline places it in adults roughly 40 to 75 with LDL cholesterol between 70 and 189 mg/dL who fall at intermediate 10-year risk (about 7.5% to under 20%), where the guideline calls CAC reasonable to guide the clinician–patient risk discussion.
It is not for everyone. The AHA is explicit that a CAC scan is not appropriate for people who already have known heart disease — including prior heart attack, stents or bypass surgery — people at very low risk, people whose treatment plan is already settled, or anyone currently having symptoms such as chest pain. Active symptoms need a different and faster workup, not a screening scan. If you are already on treatment for established coronary disease, a calcium score adds a number without adding a decision.
You can estimate where you sit before you spend anything: our heart risk check walks through the standard inputs, and cholesterol levels by age puts your lipid panel in context.
What do the numbers mean?
| Agatston score | What it means | Typical next step |
|---|---|---|
| 0 | No detectable calcified plaque. The strongest negative finding in preventive cardiology — low event rates over the following 5 to 10 years in most primary-prevention groups. | Guidelines say a "no statin" approach is reasonable in selected people, provided diabetes, current smoking and premature family history are absent. Lifestyle stays the focus. Your clinician decides. |
| 1–99 | Calcium has begun to accumulate. Mild disease is present, but the implication depends heavily on age — the same score means more in a 45-year-old than in a 72-year-old. | Judgement call. Guidelines lean toward treatment, particularly from about age 55 onward. Discussed, not automatic. |
| 100–399 | Moderate calcified plaque. Risk is meaningfully above what risk factors alone predicted for many people. | A score of 100 or more, or at or above the 75th percentile for your age, sex and race, generally supports starting preventive therapy in guideline terms. |
| 400+ | Extensive calcified plaque. Very high scores carry event risk approaching that of people with established disease. | Intensive risk-factor treatment discussion; sometimes further testing if symptoms exist. Clinician-led. |
Percentile matters alongside the absolute number. The MESA reference tool gives the 25th, 50th, 75th and 90th percentile scores for your age, sex and race — useful because a score of 50 in a 46-year-old woman is a very different signal from a 50 in a 70-year-old man. Absolute scores predict events somewhat better than percentiles, but both are worth seeing on your report.
Why the midlife-women caveat is real
Here is the nuance generic health portals skip. Women calcify later than men. In a pooled analysis of nearly 20,000 asymptomatic adults aged 30 to 45 — drawn from the CARDIA study, the CAC Consortium and the Walter Reed cohort — any detectable calcium was present in about 10% of White women and 7% of Black women, compared with 26% of White men and 16% of Black men. In that age band the sex gap is stark enough that any score above zero automatically placed a woman above the 90th percentile for her age, sex and race group.
The reassuring reading is that a zero is common and normal in younger women. The uncomfortable reading is that CAC only sees calcified plaque. Softer, non-calcified plaque — the kind more prone to rupture — does not show up. In pre- and perimenopausal women, non-calcified plaque is proportionally more of what is there. So a zero at 46 is weaker evidence of "no plaque" than a zero at 66, and it should not be treated as a permanent clearance.
MESA data on how long a zero stays trustworthy — the "warranty period" — suggests rescanning somewhere in the 3 to 7 year range depending on demographics and risk profile, with women's warranty periods clustering longer than men's and diabetes shortening that substantially (about 4.3 years versus 6.9 years in women in that analysis). None of that is a fixed schedule; it is a reason to ask your clinician when, not whether, to look again.
The wider context: women's cardiovascular risk is under-recognised, and the menopause transition shifts lipids, blood pressure and body composition in ways that are easy to write off as "just menopause." Read menopause and heart health alongside this, and know heart attack symptoms in women, which are more often missed than in men.
How strong is the evidence, really?
Strong for prediction; thinner than you might expect for proof of benefit. CAC reclassifies risk better than any other single add-on marker, and that is well replicated. But the U.S. Preventive Services Task Force reviewed calcium scoring alongside ankle-brachial index and hs-CRP and concluded that the evidence is insufficient to assess the balance of benefits and harms of adding them to traditional risk assessment in asymptomatic adults — an "I" statement, meaning not enough evidence, not evidence of no effect. The Task Force accepted that these markers improve discrimination and reclassification modestly, but judged the clinical meaning of that improvement largely unknown.
The gap is that no adequately powered randomised trial has yet shown that scanning people and acting on the result prevents more heart attacks than good risk-factor care alone. Cardiology societies weigh the reclassification data heavily; the USPSTF weighs the missing trial. Both positions are defensible, and anyone telling you this is settled is overselling. Trials testing exactly this question are ongoing.
There are real downsides too: incidental findings on the scan (lung nodules, other chest findings) that trigger further testing and worry, false reassurance from a zero, and the cost. Blood-based markers such as ApoB and lipoprotein(a) answer different questions and are not substitutes.
Radiation, time, and cost
Radiation is low. A CAC scan is commonly cited at roughly 0.89 mSv, described in the family-medicine literature as similar to a mammogram; AHA guidance holds typical doses to about 1.0 to 1.5 mSv and under 3.0 mSv, and the exact dose varies by scanner and protocol. For scale, average annual background radiation in the U.S. is about 3.1 mSv. If you are or might be pregnant, tell the imaging team — the scan is typically postponed.
Cost is where people get caught. Because it is not a covered preventive screening under most plans, and Medicare has no national coverage for it in asymptomatic primary prevention, most people pay cash. The AHA cites out-of-pocket costs of roughly $50 to $250; nationwide price samples cluster around $100 to $150, with real-world quotes spanning roughly $49 to $400. Prices vary a lot by facility and region, so call and ask for the self-pay price before you book — and verify current numbers yourself, since they move. HSA and FSA funds generally qualify. Some centres accept self-referral; many still want an order.
When to see a doctor
Do not use a calcium score to sort out symptoms. If you have chest pressure, pain or tightness, pain spreading to the jaw, neck, back or arm, sudden shortness of breath, cold sweat, nausea, or unusual crushing fatigue — especially if these come on with exertion — call 911 or go to emergency care now. Women more often present with these less classic symptoms, and they are more often dismissed. A screening scan is the wrong tool and the wrong speed for an emergency.
Book a non-urgent appointment to discuss a CAC scan if you are between about 40 and 75, have no known heart disease, and you and your clinician are genuinely undecided about preventive medication — or if you stopped a statin because of side effects and want a clearer picture before revisiting it. Bring your risk estimate, your lipid panel and your family history. Ask directly: "Would a score of 0 or a score of 300 change what we do?" If the answer is no, skip the scan.
Decisions about starting, stopping or changing any medication belong to you and your prescriber — see statins for women for what that conversation usually covers. A calcium score is a reference number that informs the discussion. It is not a diagnosis, and a single reading never tells the whole story.
]]>
